Development of Multiple Myeloma in a Patient with Chronic Myeloid Leukemia After Treatment with Imatinib Mesylate-Reference-Cited by-同舟云学术

Development of Multiple Myeloma in a Patient with Chronic Myeloid Leukemia After Treatment with Imatinib Mesylate

Published:2005-06-01 Issue:6 Volume:10 Page:457-458
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Garipidou Vassilia¹,Vakalopoulou Sofia¹,Tziomalos Konstantinos¹

Affiliation:

1. Hematology Section of Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.10-6-457

Reference4 articles.

1. Multiple myeloma preceding the development of chronic myelogenous leukemia;Nitta;Int J Hematol,1999

2. Coexistence of chronic myelogenous leukemia and multiple myeloma. Case report and review of the literature;Tanaka;Acta Haematol,1998

3. Imatinib mesylate—the new gold standard for treatment of chronic myeloid leukemia;Peggs;N Engl J Med,2003

4. Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents;Pandiella;Br J Haematol,2003

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple myeloma in a patient with chronic myeloid leukemia: A case report;Oncology Letters;2023-04-20

2. Prevalence and Clinical Characteristics of Paraproteinemia Associated with Chronic Myeloid Leukemia;Acta Haematologica;2022

3. Coexistence of multiple myeloma and chronic myeloleukosis in one patient;Russian journal of hematology and transfusiology;2020-12-10

4. Two cases of successful autologous stem cell transplantation in patients with multiple myeloma and concurrent chronic myeloid leukaemia;Bone Marrow Transplantation;2020-08-08

A case of primary gastric diffuse large B-cell lymphoma occurring in chronic myeloid leukemia

;OncoTargets and Therapy;2019-07